Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653017 | 0.88 | GPR119 (0.42) | GPR119FAAHMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10040645 | 0.86 | FAAH (0.40) | APLNRFAAH | |
| SCHEMBL10040536 | 0.82 | SPR (0.45) | FAAHMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1653033 | 0.81 | SPR (0.45) | FAAHMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10040570 | 0.81 | FAAH (0.39) | APLNRFAAHSMN1; SMN2PDK2 | |
| SCHEMBL10040646 | 0.80 | FAAH (0.43) | GPR119FAAHMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10070551 | 0.79 | AOC3 (0.45) | APLNRFAAHSMN1; SMN2CHRM4PDK2 | |
| SCHEMBL13513873 | 0.78 | KDM2A (0.45) | HDAC1HDAC2GPR119CHRM4PDK2 | |
| SCHEMBL10040589 | 0.76 | KCNH2 (0.40) | APLNRFAAHKMT2ASMN1; SMN2CHRM4 | |
| SCHEMBL10040555 | 0.75 | LMNA (0.55) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308869-B1 | AZOLE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | HDAC1 245/4885HDAC2 698/4885GPR119 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.